Objective: To evaluate the relations between PET Pittsburgh compound B (PiB-PET) binding (amyloid imaging) and plasma A␤ in patients with mild cognitive impairment (MCI) and similarly aged controls.
The amyloid ␤ peptides A␤40 and A␤42 are 2 major species in amyloid plaques in the brains of patients with Alzheimer disease (AD). 1 PET amyloid imaging with Pittsburgh compound B (PiB) shows that patients with AD have increased cortical PiB binding compared to controls, and patients with mild cognitive impairment (MCI) have levels between AD and controls. [2] [3] [4] [5] In CSF, low A␤ levels in AD have been explained by the "sink hypothesis," which postulates that increasing brain sequestration of amyloid leads to lower A␤ in CSF and plasma. 6, 7 A few studies in small samples show that increased PiB binding is associated with low CSF A␤ levels 8, 9 but there are equivocal reports. 10 In a sample of 189 healthy subjects without dementia, increased cortical PiB binding was associated with low CSF A␤42 levels but not with plasma A␤ levels. 6 In a multisite study, increased PiB cortical binding was associated with low plasma A␤42 and A␤42/40 levels across a diagnostically heterogenous sample of AD, MCI, and control subjects but not within each diagnostic group. 11 These studies were confounded by highly variable plasma A␤ values, undetectable plasma A␤ values in several subjects in one study, 6 and the use of multiple assays for plasma A␤ within each study. 11 Plasma A␤ levels are approximately onehundredth of CSF A␤ levels, leading to difficulties in accurate measurement.
We investigated the amyloid sink hypothesis by examining the associations between PiB cortical binding and plasma A␤ measures in a study of patients with amnestic MCI and healthy control subjects.
METHODS Patients of both sexes presented to a Memory
Disorders Center between September 2007 and January 2010. Inclusion criteria were age 55-90 years, a Mini-Mental State Examination (MMSE) score of 22 or higher, 12 amnestic MCI defined as subjective memory complaints, and a score Ͼ1.5 SD below norms on one of the following tests of memory: Free and Cued Selective Reminding Test immediate and delayed recall, Wechsler Memory Scale-III Visual Reproduction I and II immediate and delayed recall, and Wechsler Memory Scale-Revised Logical Memory I and II immediate and delayed recall. Patients with amnestic MCI with and without deficits in other cognitive domains were included. A comprehensive neuropsychological test battery was administered. From this battery, the MMSE (global cognition) and the 12-item 6-trial Selective Reminding Test (SRT) total and delayed recall (episodic verbal memory) were chosen a priori for statistical analyses. Key exclusion criteria were clinical stroke or cortical stroke or large subcortical lacune or infarct (Ն2 cm diameter in any MRI slice), cognitive deficits primarily due to medical conditions/medications, specific neurologic disorder (e.g., Parkinson disease, alcohol/substance abuse/dependence currently or in the past 6 months), current major depression, and history of psychosis. If inclusion and exclusion criteria were met, the final diagnosis of MCI was based on a consensus between 2 expert raters (D.P.D. and Y.S.).
Healthy control subjects, group-matched by age and sex, were recruited by local media advertising. Inclusion and exclusion criteria for controls were similar, except that cognitive criteria required MMSE score of 28 or higher and scores within 1 SD of norms on the 3 tests of memory used for MCI inclusion criteria.
Standard protocol approvals, registrations, and patient consents. The study was approved by the New York State Psychiatric Institute/Columbia University Institutional Review Board and all subjects signed informed consent.
Plasma A␤42 and A␤40. Ten-milliliter venous blood samples (tripotassium EDTA) were used to assess plasma A␤ levels. Plasma levels were measured blind to cognitive status using a combination of monoclonal antibody 6E10 (specific to an epitope present on 1-16 amino acid residues of A␤) and rabbit antisera (R165 vs A␤42 and R162 vs A␤40) in a double antibody sandwich ELISA as described previously. 13, 14 This method measures the free or soluble form of A␤, not the oligomeric or bound forms. The detection limit for these assays was 9 pg/mL. Strong test-retest and intra-assay and interassay reliability have been reported. 14 The A␤ levels from each blood draw were measured in duplicate, using separate aliquots so that none of the samples were refrozen and rethawed for the repeat assay. The means of the 2 measurements were used in statistical analyses. A␤ levels were not available for clinical diagnosis. 11 C-PiB synthesis. The full radiosynthesis of [N-Methyl 11 C]-2-(4-methylaminophenyl)-6-hydroxybenzothiazole ([ 11 C]-6-OH-BTA-1) is described elsewhere. 15 The average yield was found to be 14.5% at end of synthesis with a specific activity Ͼ37 GBq/mol. PET and MRI procedures and PET image processing are described in appendix e-1 on the Neurology Web site at www.neurology.org. [16] [17] [18] [19] [20] [21] 11 C-PiB kinetic analysis. The cerebellum is nearly devoid of amyloid plaques in patients with AD 22 and cerebellar gray matter shows little 11 C-PiB binding in healthy controls and AD. 2 Therefore, a ROI that included the entire cerebellum was drawn on the MRI. A binary mask of this ROI was created. To correct the cerebellar ROI to include gray matter only, unprocessed MRI were segmented using SPM5 to derive the probabilistic gray matter map. The gray matter map and all individual PET frames were multiplied (masked) by the cerebellar binary mask. On a frame-by-frame basis, the sum of all voxels in each masked PET image was divided by the sum of all voxels in the masked gray matter map to derive the gray matter cerebellar time activity curve.
C-PiB (BP ND ) PET modeling.
In the 39 subjects who completed the 11 C-PiB scan, binding potential (BP ND ) was calculated for each ROI using the Logan graphical method from 90-minute PET data, using the gray matter probabilitycorrected time activity curve of the cerebellum as reference. 23 For comparison to other reports, distribution volume ratio (DVR) ϭ BP ND ϩ 1.
Statistical analyses.
Descriptive statistics were used to compare the demographic and clinical variables in patients with MCI and cognitively intact control subjects. Preliminary analyses examined bivariate correlations between 11 C-PiB BP ND (binding potential, cerebellar reference) in the cingulate, parietal, and parahippocampal regions, and the A␤ measures (A␤40, A␤42, A␤42/A␤40 ratio), with demographic and cognitive variables.
Linear regression analyses were conducted on each of the 3 PiB measures, adjusting for age and sex, with each of the A␤ measures as predictors. These analyses were repeated after also including a global cognitive measure (MMSE) or episodic verbal memory measures (SRT total recall or delayed recall) as covariates. PiB binding was classified a priori as high binding if BP nd was greater than 0.35 (equivalent to DVR greater than 1.35) and the associations between low and high PiB binding and the A␤ measures were evaluated. This cutoff was nearly 2 SD above the control mean value and is in the midrange of different cutoffs used in the literature. 5, 24 RESULTS There were 20 patients with MCI and 19 cognitively intact control subjects. Patients with MCI were recruited from 89 patients assessed for eligibility; 29 were eligible and 20 agreed to participate in the study. Control subjects were recruited from 102 subjects assessed for eligibility; 33 were eligible and 19 agreed to participate in the study. Demographic and clinical data are provided in table 1. Plasma A␤40 and A␤42 levels did not correlate significantly with each other so they were analyzed separately. In the total sample and separately in the MCI and control groups, none of the plasma A␤ measures were related to age, sex, MMSE, or SRT total recall or delayed recall. In patients with MCI compared to controls, the A␤42/A␤40 ratio was lower and plasma A␤42 tended to be lower (t ϭ 1.93, p ϭ 0.06) with no difference in A␤40 levels (t ϭ 1.0, p ϭ 0.3).
PiB binding in each of the 3 regions was unrelated to age or sex. Increased PiB binding in cingulate, parietal, and total brain was associated with lower MMSE and SRT total and delayed recall (rs ϭ Ϫ0.32 to Ϫ0.42, ps Ͻ 0.01 to 0.05). Increased PiB binding in the prefrontal cortex was associated with lower SRT total (r ϭ Ϫ0.34, p ϭ 0.03) and delayed recall (r ϭ Ϫ0.33, p ϭ 0.04) but not MMSE. Increased PiB binding in the parahippocampal gyrus was associated with lower MMSE (r ϭ Ϫ0.37, p ϭ 0.02) but not lower SRT total or delayed recall. PiB BP nd was increased in MCI compared to controls in the cingulate ( p ϭ 0.02), parietal ( p ϭ 0.02), and total brain ( p ϭ 0.03), but not in prefrontal cortex ( p ϭ 0.08) or parahippocampal gyrus ( p ϭ 0.07).
Relation of plasma ␤-amyloid peptides to PiB PET levels. In the total sample, in linear regression analyses adjusting for age and sex, all 3 measures of plasma A␤ were significantly related to PiB in parietal cortex, and A␤40 and the A␤42/A␤40 ratio were significantly related to PiB in cingulate (table 2) . Higher A␤40 and lower A␤42/A␤40 ratio were significant for cingulate in these analyses ( p ϭ 0.02 and p ϭ 0.02, respectively) and lower A␤42/A␤40 ratio was significant for parietal cortex in similar analyses ( p ϭ 0.01). Two healthy control subjects had high A␤42/ A␤40 ratio (figure). After excluding these 2 subjects, in linear regression analyses adjusting for age and sex, the results did not change appreciably for cingulate (A␤40 p ϭ 0.02, A␤42 p ϭ 0.06, A␤42/A␤40 ratio p ϭ 0.002) and parietal cortex (A␤40 p ϭ 0.06, A␤42 p ϭ 0.02, A␤42/A␤40 ratio p ϭ 0.001). In similar linear regression analyses, the relations be-tween plasma A␤ peptide measures and PiB binding in the prefrontal cortex or the parahippocampal gyrus did not reach significance. Higher plasma A␤40 ( p ϭ 0.04) and lower A␤42/A␤40 ratio ( p ϭ 0.02), but not A␤42, were related to total brain PiB binding (table 2). The directions of the associations between plasma A␤40 and PiB binding (positive association) and between both A␤42 and A␤42/A␤40 ratio with PiB binding (negative association) were consistent across the PiB measures examined (table 2) .
The linear regression analyses for cingulate and parietal cortex, and total brain PiB binding, were repeated with age, sex, each of the A␤ measures, and MMSE or SRT immediate or delayed recall as covariates. In these analyses, the association of lower A␤42 and A␤42/A␤40 ratio with higher cingulate and parietal and total brain PiB binding remained at similar significance levels with the A␤42/A␤40 ratio being significant (0.01 Ͻ p Յ 0.05) in all of these analyses.
The figure shows the relation of the A␤42/A␤40 ratio to PiB by MCI status in the cingulate and parietal cortex. Approximately half of the participants with MCI showed elevated PiB binding and most controls did not show elevated PiB binding. The difference in PiB binding between subjects with MCI and controls was greatest in the parietal region in linear regression analyses adjusted for age and sex (MCI mean ϭ 0.33, control mean ϭ 0.12, p ϭ 0.032). In exploratory analyses within PiB positive subjects (n ϭ 9), the correlations between PiB binding measures and plasma A␤ levels were strong in PiB-positive subjects but not in PiB-negative subjects (table 3) . Within the MCI group, high cingulate, high parietal, and total PiB binding were associated with a lower A␤42/A␤40 ratio ( ps ϭ 0.02 to 0.03). Seven patients with MCI and 2 control subjects showed high binding in the cingulate and parietal regions. Of the 7 patients with MCI who had high PiB binding (Ͼ0.35), 6 had low A␤42/40 levels (Ͻ0.16). One of the 2 controls with high PiB binding had low A␤4240 ratio. Five patients with MCI had normal PiB and normal A␤ levels.
DISCUSSION
The plasma A␤42/A␤40 ratio, and to a lesser extent plasma A␤42, were decreased in patients with MCI compared to cognitively intact control subjects, consistent with the literature. [3] [4] [5] 19 Increased PiB binding in the cingulate and parietal cortex, as well as increased total brain PiB binding, have been shown to occur in MCI compared to controls. 3, 4 The increase in prefrontal cortex binding was not as strong as in the initial PiB report 2 but is consistent with subsequent reports which showed that the precuneus or parietal cortex rather than prefrontal cortex manifests the greatest differences between AD and controls. 3, 4 The relative sparing of the parahippocampal gyrus is consistent with the literature showing low binding in the medial temporal lobe with amyloid brain imaging. [2] [3] [4] 19 Increased PiB binding in the cingulate and parietal cortex, and total brain, was associated with decreased plasma A␤42 and the A␤42/A␤40 ratio, and these associations remained significant even after controlling for age, sex, and cognitive test scores. The resilience of this finding in this sample supports the hypothesis that increased amyloid deposition in the brain is accompanied by lower peripheral A␤ levels in plasma. This association between PiB binding and plasma A␤ was strong in PiB-positive subjects and weak to absent in PiB-negative subjects, further supporting the sink hypothesis that increased sequestration of amyloid in the brain is associated with decrease in peripheral A␤ levels.
There was an increase in plasma A␤40 levels associated with PiB binding that varied depending on which ROI was examined (table 2). In a metaanalysis of 4 studies that examined plasma A␤ measures but without amyloid imaging, an increase in plasma A␤40 levels, but not A␤42 or the A␤42/ A␤40 ratio, was weakly associated with MCI conversion to AD. 25 In AD, there is decreased clearance of both A␤40 and A␤42 without any difference in production rates. 26 A␤42 plays a critical role in the pathogenesis of AD because A␤42 aggregates much faster and is more toxic than A␤40. 27 A minor increase in the A␤42/A␤40 ratio stabilizes toxic oligomeric species with intermediate conformations, and the relative ratio of A␤ peptides is more important than the absolute amounts of peptides for the induction of neurotoxic conformations. 28 Overall, A␤42 and the A␤42/A␤40 ratio appear to be related to the pathogenesis of AD while A␤40 may be related more to amyloid deposition in vessel walls and cerebral amyloid angiopathy. 29 We found that an increase in plasma A␤40 levels was associated with cingulate, parietal, and total brain PiB binding, but the A␤42/ A␤40 ratio was the plasma measure that showed the most consistent and robust associations with PiB binding across the ROIs examined.
Within the MCI group, 6 of 7 patients with high PiB binding had low plasma A␤ levels. This association was present in only one control subject, and this subject may show evidence of cognitive decline and AD when followed over time. A larger study that examined healthy elderly subjects, and did not explicitly include patients with MCI, did not observe the association between plasma A␤ levels and PiB binding. 6 Further, in that study the authors acknowledged that there was variability in assay procedures with plasma A␤ levels below the limit of detection in several samples, 6 which did not occur in our study. An earlier report in a small series from the same re-search group found no association between PiB binding and plasma A␤ in 18 healthy controls and 6 patients with dementia of whom 4 had AD. 30 The AIBL study of aging found associations between PiB and plasma A␤ across their entire sample that were similar to the findings in our study, but the associations within each diagnostic group were not significant. 11 The authors emphasized the poor reliability that arose from using multiple, discrepant assays of plasma A␤. 11 The highly variable levels of plasma A␤42 and A␤40 in different studies, 13, [31] [32] [33] [34] and the reported lack of significant associations between levels of A␤ in plasma and CSF, 14, 35 may, in part, be explained by the variability and poor reliability of assays for plasma A␤ levels, i.e., there may indeed have been an association that was obscured by the excessive variability in the results from the plasma assay. In our study, we used a single assay with established low intraclass coefficients and high test-retest reliability, 7 thereby strengthening the reliability of the plasma A␤ findings.
Increased amyloid deposition in the brain may occur several years to decades before clinically manifest symptoms. 36 Reduction in CSF A␤42, likely reflecting A␤ aggregation in the brain, is associated with brain atrophy on structural MRI in the preclinical phase of AD, suggesting that A␤ aggregation leads to toxicity before clinically detectable disease. 37 A similar reduction in plasma A␤ may occur, as our group showed in a longitudinal study of a multiethnic community sample in which initially elevated plasma A␤42 in healthy elderly was followed over time by significant reduction in plasma A␤42 and A␤42/40 levels in association with the clinically diagnosable onset of AD. 7, 38 Increases in CSF tau (and ptau181) may be later events associated with further structural brain damage closer to the clinical onset of AD. 37 Our finding of increased PiB uptake being associated with lower plasma A␤ levels in MCI supports this proposed timeline of disease progression in the brain, and suggests that plasma A␤ may be similar to CSF A␤ in showing associations with PiB binding. One limitation is that we did not assess CSF A␤ systematically in this sample. Drawing blood is more feasible and acceptable to patients than withdrawal of CSF, but CSF A␤, tau, and phospho-tau levels clearly have strong predictive utility for conversion to AD. Combining PiB PET with plasma A␤ may have potential clinical application if this combination is found to be more useful than PiB binding or plasma A␤ alone in improving diagnostic accuracy or predicting outcome, and CSF markers if available may further enhance diagnostic accuracy and prediction. Prediction of outcome requires longitudinal data. Continued follow-up, which has begun in our sam-ple, will also help to clarify if patients with MCI who have increased PiB binding and decreased A␤42 levels have a high conversion rate to the clinical diagnosis of AD, and if patients with MCI who do not have increased PiB binding and low plasma A␤ levels do not convert to AD.
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